Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5471713 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants receiving GSK5471713 | EXPERIMENTAL | Participants will receive GSK5471713, according to their allocated dose level guided by the dose escalation study design. |
| Name | Type | Description |
|---|---|---|
| GSK5471713 | DRUG | GSK5471713 will be administered at different dose levels based on the dose escalation study design |
Inclusion Criteria: * Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate. * Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT). * Eastern Cooperative Oncology Group (ECOG) performance statu...
GSK5471713 is an investigational small molecule being developed for the treatment of prostate neoplasms, specifically metastatic castration-resistant prostate cancer (mCRPC). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GSK5471713 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting a first-time-in-human study of this investigational drug in adults with mCRPC.
GSK5471713 is in Phase 1 clinical development. It is currently being evaluated in a first-time-in-human study that is recruiting participants. The drug is investigational and has not received regulatory approval for any indication.
GSK5471713 is being studied in a Phase 1 clinical trial with the identifier NCT07332455. This is a first-time-in-human study in adults with metastatic castration-resistant prostate cancer (mCRPC), enrolling 54 participants across the United States, Australia, Canada, Japan, and South Korea.
GSK5471713 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials, meaning it is still in the early stages of clinical development and has not been evaluated for safety and efficacy in large-scale studies.